Drug and Therapeutics Bulletin 1996;34:23-24; doi:10.1136/dtb.1996.34323
Copyright © 1996 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Inhaled budesonide and adrenaline for croup

Relevant BNF section: 3.2

Croup (laryngotracheobronchitis) is a common respiratory disease of childhood with a peak incidence in the second year. Symptoms are often distressing to both child and parent, and severe croup can threaten life. About 1 in 10 children with croup is admitted to hospital and of these 1 in 20 needs active intervention to maintain the airway or treat respiratory failure.1 In the USA nebulised adrenaline has become standard treatment for children with moderate or severe croup but is less widely used in the UK and is unlicensed. More recently nebulised budesonide has been promoted as first line treatment for mild to severe croup. In this article we review these two approaches.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1996 BMJ Publishing Group Ltd.